Abiopharma

🔍 DUNCAN BARBARA GAYLE (Director)

Company: HALOZYME THERAPEUTICS, INC. (HALO)

Report Date: 2026-05-05

Detailed Transactions and Holdings:

• Acquired 3,796 shares of Common Stock (Direct)
  Date: 2026-05-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 23,715.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 6,040 shares of Option to Purchase Common Stock at $65.87 per share (Derivative)
  Date: 2026-05-05 | Code: A | Expires: 2036-05-05 | equity_swap_involved: 0 | shares_owned_after: 6,040.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.
• F2: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.